Colossal Biosciences just dropped its most ambitious tech play yet – an AI platform designed to fast-track the company’s moonshot mission of bringing extinct species back to life. The Dallas-based startup, already valued at $1.5 billion, is betting that artificial intelligence can solve the complex genetic puzzles that have slowed de-extinction research for decades. Peter Diamandis has backed the move with a new fund specifically targeting startups that leverage the platform.
The de-extinction game just got its biggest tech upgrade. Colossal Biosciences, the company trying to bring back woolly mammoths and Tasmanian tigers, announced today it’s opening up its AI-powered research platform to the broader scientific community – and investors are already lining up.
The timing couldn’t be more strategic. While Colossal has raised over $225 million since 2021, the company’s core mission – literally resurrecting extinct species – faces massive technical hurdles that could take decades to overcome. By platformizing its AI tools, the startup is creating a new revenue stream while positioning itself as the infrastructure backbone for next-generation biotech.
Peter Diamandis, the XPRIZE founder who’s been bullish on longevity and biotech investments, didn’t waste time. He’s launching a dedicated fund to back startups that build on Colossal’s platform, essentially betting that the company’s AI tools will spawn an entire ecosystem of genetic engineering applications.
The platform leverages machine learning to tackle some of the most complex challenges in genetic engineering – from predicting how ancient DNA sequences might function in modern cellular environments to optimizing CRISPR edits for maximum accuracy. What took Colossal’s team months of trial and error can now be modeled and tested virtually before any lab work begins.
This isn’t just about bringing back mammoths anymore. The AI platform could accelerate research into everything from crop resilience to rare disease treatments. By making these tools available to smaller research teams and startups, Colossal is essentially democratizing access to cutting-edge genetic engineering capabilities that were previously locked behind massive R&D budgets.
The competitive implications are huge. While companies like Ginkgo Bioworks have built platforms for synthetic biology, Colossal’s focus on extinct species has forced them to solve uniquely challenging problems around incomplete genetic data and cellular compatibility. Those solutions now become competitive advantages in the broader biotech market.
Diamandis’s fund signals that investors see Colossal as more than a science experiment. The company is building the picks and shovels for a new gold rush in genetic engineering, where the real money might not be in the headline-grabbing de-extinction projects but in the infrastructure that makes thousands of smaller innovations possible.
For Colossal, the platform launch solves a critical business model question. De-extinction timelines are measured in decades, but platform revenue can start flowing immediately. Every startup that uses their AI tools to design better gene therapies or engineer more resilient crops validates the underlying technology while generating cash flow to fund the moonshot projects.
The biotech industry has been waiting for this kind of infrastructure play. Most genetic engineering startups spend years building basic computational tools before they can focus on their core research. Colossal’s platform could compress that timeline from years to months, potentially unleashing a wave of innovation across multiple sectors.
Colossal Biosciences is making a smart pivot from pure research play to platform provider, creating immediate revenue opportunities while advancing their long-term de-extinction goals. With Diamandis backing the ecosystem play, we’re likely seeing the emergence of a new category in biotech infrastructure. The real test will be whether the platform can deliver the promised acceleration in genetic engineering timelines – and whether enough startups adopt it to create the network effects that make platforms truly valuable.